AI Access Brief Podcast

Episode 168 — 15 November 2026 Examining evolving value frameworks for gene therapies, focusing on evidence requirements, threshold adjustments, and payment model innovations. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast

Episode 167 — 14 November 2026 Examining HCA's profit warning as a signal of access erosion, subcutaneous Leqembi's implications, FTC's insulin settlement impact, and ICER's early-phase advice expansion. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast

Episode 166 — 12 November 2026 HCA's profit warning signals US access erosion; subcutaneous Leqembi reshapes Alzheimer's value narrative; FTC-CVS insulin settlement exposes PBM practices; ICER early-phase advice aims to de-risk development. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at out...

Episode 165 — 11 November 2026 Examining systemic access pressures from hospital operators, new Alzheimer's evidence demands, PBM pricing transparency, and proactive HEOR strategies. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast

Episode 164 — 10 November 2026 FDA updates RWE standards for post-marketing studies, FTC cracks down on PBM insulin pricing, ICER expands early-phase advice, and HCA's profit warning signals systemic access challenges. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast

Episode 163 — 08 November 2026 HCA's profit warning signals US access erosion; subcutaneous Leqembi reshapes Alzheimer's value narrative; FTC-CVS insulin settlement exposes PBM practices; ICER early-phase advice aims to de-risk development. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at out...

Episode 162 — 07 November 2026 This week, we cover the FDA's draft guidance on real-world evidence, the FTC's settlement with CVS Caremark, ICER's expansion of early-phase scientific advice, and NICE's updated guidance on real-world evidence for technology appraisals. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landsca...

Episode 161 — 06 November 2026 CMS launches VBID model for chronic conditions, NICE revises surrogate endpoint frameworks, and FDA releases DCT guidance for oncology drugs. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast

Episode 160 — 05 November 2026 Examining evolving HTA methodologies, RWE integration challenges, and operational hurdles in US/EU access frameworks. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast

Episode 159 — 04 November 2026 Examining new FDA guidance on RWE for post-marketing studies, FTC's landmark insulin pricing settlement with CVS, CMS Star Rating changes, and ICER's expanded early-phase scientific advice program. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analyt...

Episode 158 — 03 November 2026 Examining how ESG metrics reshape drug pricing, RWE's expanding role in HTA, and the impact of AI on evidence generation. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast

Episode 157 — 02 November 2026 HCA signals access erosion in US healthcare; new subcutaneous Leqembi approved; FTC settles with CVS Caremark over insulin pricing; ICER expands scientific advice to pre-Phase 3. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast

Episode 156 — 01 November 2026 This episode examines FDA's new RWE guidance, CMS Star Rating changes, NICE's digital therapeutics framework, and the first wave of EU oncology JCAs. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast

Episode 155 — 31 October 2026 Examining FDA's RWE guidance for post-marketing studies, CMS's new hospital value model, ISPOR's digital therapeutics framework, and EMA's AI reflection paper. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast

Episode 154 — 30 October 2026 Examining HCA's profit warning as an access erosion signal, subcutaneous Leqembi's HEOR implications, FTC-CVS insulin settlement impact on PBMs, and ICER's early-phase scientific advice expansion. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-ana...

Episode 153 — 29 October 2026 CMS overhauls Star Ratings methodology, NICE advances digital health assessment, EU launches oncology JCAs, and FDA expands RWE use for rare diseases. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast

Episode 152 — 28 October 2026 Examining HCA's profit warning as a bellwether for US healthcare access erosion, analyzing subcutaneous Leqembi's HEOR implications, and dissecting the FTC-CVS insulin settlement's impact on PBM practices. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at out...

Episode 151 — 27 October 2026 FDA approves subcutaneous Leqembi; FTC settles insulin pricing case; ICER expands early-phase advice; HCA profit warning flags US access challenges. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast

Episode 150 — 26 October 2026 Examining US healthcare access erosion, Alzheimer's treatment evolution, PBM pricing practices, and early-phase evidence strategy reshaping. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast

Episode 149 — 25 October 2026 Examining evolving HTA evidence frameworks, IRA implications for evidence strategies, patient-centered endpoint integration, and gene therapy cost-effectiveness hurdles. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast

Episode 148 — 24 October 2026 Examining systemic access challenges, novel Alzheimer's administration shifts, PBM reform implications, and early HEOR integration in development. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast

Episode 147 — 23 October 2026 Examining operational hurdles in CMS Part D redesign, evolving FDA RWE guidance, NICE's RWE framework updates, and the first wave of oncology JCAs under EU HTA. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast

Episode 146 — 22 October 2026 HCA's profit warning signals US healthcare access erosion; subcutaneous Leqembi approval transforms Alzheimer's value evidence; FTC-CVS insulin settlement exposes PBM pricing practices; ICER expands early-phase scientific advice to align development with HTA needs. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the eviden...

Episode 145 — 21 October 2026 Examining evolving HTA frameworks across emerging markets and digital health evidence integration challenges. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast

Episode 144 — 20 October 2026 Examining HCA's access crisis, subcutaneous Leqembi's value shift, insulin pricing reforms, and ICER's evidence strategy evolution. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast